Studies of the T-cell angiotensin receptor using cre-lox technology: an unan-T-cellpated result.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. Innate Immune Cells Are Regulated by Axl in Hypertensive Kidney.The American journal of pathology · 2018
   Article
2. Interactions Between the Immune and the Renin-Angiotensin Systems in Hypertension.Hypertension (Dallas, Tex. : 1979) · 2016
   Review
3. Role of Axl in early kidney inflammation and progression of salt-dependent hypertension.Hypertension (Dallas, Tex. : 1979) · 2013
   Article
4. The role of type 1 angiotensin receptors on T lymphocytes in cardiovascular and renal diseases.Current hypertension reports · 2013
   Article

Corrections and comments

• Comment on
  A novel role for type 1 angiotensin receptors on T lymphocytes to limit target organ damage in hypertension.2012

Authors and funding

2 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as